ArticleBMC gastroenterology2025
Cardiometabolic Index as a predictor of mortality in metabolic Dysfunction-Associated Steatotic Liver Disease.
Article in BMC gastroenterology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCardiometabolic Index (CMI) is positively correlated with liver fibrosis in patients with Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), but its association with mortality risk in MASLD patients remains unclear.
methodsThis study utilized data from NHANES III and linked it with the mortality database up to December 31, 2019. Cox regression analysis was used to examine the relationship between CMI and mortality rates. Linear regression analysis was conducted to explore the correlation between CMI and the TyG index, and mediation analysis was performed to investigate the potential mechanisms underlying the association between CMI and mortality.
resultsThe study included 2,260 MASLD patients with a median age of 51 years and a median CMI of 2.5. In the fully adjusted Cox regression model, CMI was positively associated with all-cause mortality (per 1-SD increase, HR = 1.04, 95% CI = 1.00-1.08) and other-cause mortality rates (per 1-SD increase, HR = 1.25, 95% CI = 1.12–1.40), but not with cardiovascular or cancer-related mortality. Mediation analysis indicated that the TyG index mediated 16.6% of the association between CMI and all-cause mortality.
conclusionCMI in MASLD patients is associated with an increased risk of all-cause and other-cause mortality.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.